Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| AMGEN | 16 | 27 | +2,78 % | ||
| THIRD HARMONIC BIO | 12 | 2 | 0,00 % | ||
| VERVE THERAPEUTICS | 9 | - | 0,00 % | ||
| IRONWOOD PHARMACEUTICALS | 4 | - | -31,93 % | ||
| FATE THERAPEUTICS | 4 | - | -11,78 % | ||
| BIONTECH | 3 | 13 | +9,13 % | ||
| IDEAYA BIOSCIENCES | 3 | 3 | -1,35 % | ||
| VIATRIS | 3 | 2 | +1,45 % | ||
| STRUCTURE THERAPEUTICS | 3 | 1 | +19,25 % | ||
| NEUROCRINE BIOSCIENCES | 2 | 17 | +3,20 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:15 | Astrazeneca Aktie: Details zum strategischen Plan | 162 | Börse Global | Trotz aktueller Schwächephase halten Analysten an Kaufempfehlungen fest - Dividendenankündigung und Quartalszahlen im Fokus. Die AstraZeneca-Aktie zeigt sich diese Woche widersprüchlich: Während Aktionäre... ► Artikel lesen | |
| 00:45 | Bristol Myers Slumps On Heart Drug Failure - Taking Cytokinetics With It | 7 | Investor's Business Daily | ||
| 00:12 | Applied Therapeutics GAAP EPS of -$0.76 beats by $0.57, revenue of $0.5M misses by $0.05M | 1 | Seeking Alpha | ||
| Mo | Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results | 3 | GlobeNewswire (USA) | ||
| Mo | DelveInsight Business Research, LLP: FDA Approval of Amgen's UPLIZNA for IgG4-related Disease Opens New Market Opportunity in Rare Autoimmune Segment | DelveInsight | 203 | PR Newswire | With UPLIZNA receiving a label expansion that opens the door to a previously untapped rare disease market, Amgen is seeing strong returns on its USD 27.8 billion acquisition of Horizon Therapeutics.... ► Artikel lesen | |
| Mo | Assessing Verve Therapeutics: Insights From 4 Financial Analysts | 1 | Benzinga.com | ||
| Mo | Neurogene Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Mo | SUTRO BIOPHARMA, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| Mo | Jim Cramer on Recursion (RXRX): "The AI Company That Has It - Backed by Jensen Huang and NVIDIA" | 8 | Insider Monkey | ||
| Mo | Absci Corporation: Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025 | 1 | GlobeNewswire (USA) | ||
| Mo | Amgen bumps up pay for longtime CEO Robert Bradway 8% to $24.4M | 3 | FiercePharma | ||
| Mo | What 5 Analyst Ratings Have To Say About Medpace Holdings | 1 | Benzinga.com | ||
| Mo | Die Biogen-Aktie heute stark: Kurs legt deutlich zu (104,8787 €) | 278 | ARIVA.de | Zu den großen Gewinnern am Aktienmarkt zählt am Montag der Anteilsschein von Biogen . Der Kurs des Papiers legt kräftig zu. Grund zur Freude haben Aktionäre von Biogen: Die Aktie weist zur Stunde ein... ► Artikel lesen | |
| Mo | Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug | 3 | Benzinga.com | ||
| Mo | Piper Sandler maintains Amgen stock Overweight with $329 target | 7 | Investing.com | ||
| Mo | Sandoz Files Antitrust Lawsuit Against Amgen Over Enbrel Market Practices | 4 | CPI | ||
| Mo | Third Harmonic outlines plans for dissolution | 2 | BioPharma Dive | ||
| Mo | Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug | 6 | Benzinga.com | ||
| Mo | GENMAB A/S - 6-K, Report of foreign issuer | 4 | SEC Filings |
Seite:
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
